TTNP: Titan Pharmaceuticals, Inc. (de) Company Profile & Statistics

About

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Info & Links

CEO

David E. Lazar

Headquarters

400 OYSTER POINT BLVD, SUITE 505
SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

WithumSmith+Brown, PC

Share holders

Employees

Titan Pharmaceuticals, Inc. (de) Statistics

Valuation Measures

Market Capitalization²

3.29M

Enterprise Value

-806.90K

Enterprise Value/EBITDA(ttm)

0.11

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

10.64

Price to Book(mrq)

0.82

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-2112.50%

Return on Equity(ttm)

-87.90%

Return on Invested Capital(ttm)

-103.63%

Return on Assets(ttm)

-75.11%

Income Statement

Revenue(ttm)

3.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

3.00K

EBITDA(ttm)³

-7.07M

Net Income Available to Common(ttm)

-5.46M

Diluted EPS(ttm)

Share Statistics

Beta (5Y Monthly)

1.12

52-Week Change

-46.91%

S&P 500 52-Week Change

26.88%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

914.23K

Dividend Yield

0.00%

Float⁴

686.00K

% Held by Insiders

24.93%

% Held by Institutions

31.49%

Balance Sheet

Total Cash(mrq)

4.09M

Total Cash Per Share(mrq)

4.48

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.22%

Quick Ratio(mrq)

12.22%

Book Value Per Share(mrq)

4.37

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.93

Free Cash Flow(ytd)

-2.68M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TTNP

Titan Pharmaceuticals, Inc. (de)

Titan Pharmaceuticals, Inc. (de) Profile